Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features

References

• Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behcet’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Anti- Gens. 1999;54:213–220. doi:https://doi.org/10.1034/j.1399-0039.1999.540301.x.
   Google Scholar
• Luigi. Criteria for diagnosis of Behçet’s disease. International study group for Behçet’s disease. Lancet. 1990;335(8697):1078–1080.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–380. doi:https://doi.org/10.1016/j.ajo.2004.03.022.
   PubMed Web of Science ®Google Scholar
• Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behçet’s disease: an international collaborative study. Br J Ophthalmol. 2007;91:1578–1582. doi:https://doi.org/10.1136/bjo.2007.123554.
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Akazawa K, Nishioka Y, Sanui H, Inomata H, Nose Y. Prognostic factors of vision in patients with Behçet disease. Ophthalmology. 1995;102:317–321. doi:https://doi.org/10.1016/S0161-6420(95)31022-6.
   PubMed Web of Science ®Google Scholar
• Demiroglu H, Barista I, Dundar S. Risk factor assessment and prognosis of eye involvement in Behçet’s disease in Turkey. Ophthalmology. 1997;104:701–705. doi:https://doi.org/10.1016/S0161-6420(97)30249-8.
   PubMed Web of Science ®Google Scholar
• Yu HG, Kim MJ, Sewoong F. Fluorescein angiography and visual acuity in active uveitis with Behçet disease. Ocul Immunol Inflamm. 2009;17:41–46. doi:https://doi.org/10.1080/09273940802553279.
   PubMed Web of Science ®Google Scholar
• Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med. 1990;322:281–285. doi:https://doi.org/10.1056/NEJM199002013220501.
   PubMed Web of Science ®Google Scholar
• Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease. Lancet. 1989;1:1093–1096. doi:https://doi.org/10.1016/S0140-6736(89)92381-7.
   PubMed Web of Science ®Google Scholar
• Yazici H, Hatemi G. Empiricism in managing Behcet’s syndrome. Clin Exp Rheumatol. 2012;30:S7–9.
   Web of Science ®Google Scholar
• Okada AA, Goto H, Ohno S, Mochizuki M. Ocular Behcet’s disease research group of japan. multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592–598. doi:https://doi.org/10.1001/archophthalmol.2011.2698.
   PubMed Web of Science ®Google Scholar
• Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behc ̧ et disease. Br J Ophthalmol. 2011;95:549–552. doi:https://doi.org/10.1136/bjo.2009.174888.
   PubMed Web of Science ®Google Scholar
• Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet’s disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245–1250. doi:https://doi.org/10.1136/bjo.2010.194464.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum. 2005;52:2478–2484. doi:https://doi.org/10.1002/art.21231.
   PubMed Web of Science ®Google Scholar
• Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet’s disease: a 24-month follow-up study. Rheumatology. 2007;46:1161–1164. doi:https://doi.org/10.1093/rheumatology/kem101.
   PubMed Web of Science ®Google Scholar
• Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575–1581. doi:https://doi.org/10.1016/j.ophtha.2012.02.018.
   PubMed Web of Science ®Google Scholar
• Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm. 2010;18:226–232. doi:https://doi.org/10.3109/09273948.2010.483314.
   PubMed Web of Science ®Google Scholar
• Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int. 2011;31(2):243–245. doi:https://doi.org/10.1007/s00296-009-1178-y.
   PubMed Web of Science ®Google Scholar
• Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet’s disease: experience in 19 patients. Rheumatology. 2012;51:1825–1831. doi:https://doi.org/10.1093/rheumatology/kes130.
   PubMed Web of Science ®Google Scholar
• Calvo Catalá J, Campos Fernández C, Rueda Cid A, González-Cruz Cervellera MI, Baixauli Rubio A, Pastor Cubillo MD. Efficacy of adalimumab in Behçet’s disease. Description of 6 cases. Reumatol Clin. 2011;7:58–61. doi:https://doi.org/10.1016/j.reuma.2010.10.003.
   Google Scholar
• Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C. New approaches in the treatment of Adamantiades-Behcet’s disease. Curr Opin Rheumatol. 2006;18:3–9. doi:https://doi.org/10.1097/01.bor.0000197995.27579.9b.
   PubMed Web of Science ®Google Scholar
• Wardiana A, Ningrum RA. Roferon-A: a biologic product of human interferon alpha 2a. Annales Bogorienses-J Trop Gen Bot. 2015;19(2):1–11.
   Google Scholar
• Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423–431. doi:https://doi.org/10.1136/bjo.87.4.423.
   PubMed Web of Science ®Google Scholar
• Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146:837–844.e1. doi:https://doi.org/10.1016/j.ajo.2008.08.038.
   PubMed Web of Science ®Google Scholar
• Diwo E, Gueudry J, Saadoun D, Weschler B, LeHoang P, Bodaghi B. Long-term efficacy of interferon in severe uveitis associated with Behçet disease. Ocul Immunol Inflamm. 2017;25(1):76–84. doi:https://doi.org/10.1080/09273948.2016.1206204.
   PubMed Web of Science ®Google Scholar
• Yalçindag N, Köse HC. Comparison of the treatment results for behçet uveitis in patients treated with infliximab and interferon. Ocul Immunol Inflamm. 2020;28(2):305–314. doi:https://doi.org/10.1080/09273948.2019.1606256.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Interferon-alpha ST. 2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvasc Res. 1995;49(3):277–288. doi:https://doi.org/10.1006/mvre.1995.1024.
   PubMed Web of Science ®Google Scholar
• Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012;20(1):18‐26. doi:https://doi.org/10.3109/09273948.2011.633205.
   Google Scholar
• Huizinga T, Knevel R. Rheumatoid arthritis: 2014 treat-to- target RA recommendations - strategy is key. Nat Rev Rheumatol. 2015;49:277–288.
   Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
   Web of Science ®Google Scholar
• Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study. Ophthalmology. 2014;121:1877–1884. doi:https://doi.org/10.1016/j.ophtha.2014.04.042.
   PubMed Web of Science ®Google Scholar
• Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multi- center study of 124 patients. J Autoimmun. 2015;62:67–70. doi:https://doi.org/10.1016/j.jaut.2015.06.005.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(786–96):e3. doi:https://doi.org/10.1016/j.ophtha.2013.09.048.
   Google Scholar
• Keino H, Okada AA, Watanabe T, Taki W. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet’s disease. Eye. 2014;28(9):1100–1106. doi:https://doi.org/10.1038/eye.2014.138.
   PubMed Web of Science ®Google Scholar
• Markomichelakis, Markomichelakis NN, Aissopou EK, et al. Biologic treatment options for retinal neovascularization in Behçet’s disease. Ocul Immunol Inflamm. 2019;27(1):51–57. doi:https://doi.org/10.1080/09273948.2017.1332228.
   PubMed Web of Science ®Google Scholar
• Y A S, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987;47:5155–5161.
   PubMed Web of Science ®Google Scholar
• Sullu Y, Alotaiby H, Beden U, Erkan D. Pars plana vitrectomy for ocular complications of Behçet’s disease. Ophthalmic Surg Lasers Imaging. 2005;36(4):292–297. doi:https://doi.org/10.3928/1542-8877-20050701-07.
   PubMedGoogle Scholar
• Glaser BM. Extracellular modulating factors and the control of intraocular neovascularization. An overview. Arch Ophthalmol. 1988;106(5):603–607. doi:https://doi.org/10.1001/archopht.1988.01060130657020.
   PubMedGoogle Scholar
• De Simone L, Sangiovanni A, Aldigeri R, et al. Interferon alpha-2a treatment for post-uveitic refractory macular edema. Ocul Immunol Inflamm. 2020;28(2):322‐328. doi:https://doi.org/10.1080/09273948.2019.1589526.
   Google Scholar
• Invernizzi A, Iannaccone F, Marchi S, et al. Interferon alpha-2a for the treatment of post-infectious uveitis secondary to presumed intraocular tuberculosis. Ocul Immunol Inflamm. 2019;27(4):643‐650. doi:https://doi.org/10.1080/09273948.2018.1431292.
   Google Scholar
• Deuter CME, Koetter I, Guenaydin I, Stuebiger N, Zierhut M. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006;26:786–791. doi:https://doi.org/10.1097/01.iae.0000244265.75771.71.
   PubMed Web of Science ®Google Scholar
• Deuter CME, KÖtter I, GÜnaydin I, StÜbiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of intereron alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906–913. doi:https://doi.org/10.1136/bjo.2008.153874.
   PubMed Web of Science ®Google Scholar
• Deuter C, Stubiger N, Zierhut M. Interferon-alpha therapy in noninfectious uveitis. Dev Ophthalmol. 2012;51:90–97.
   PubMedGoogle Scholar
• Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon- associated retinopathy. Arch Ophthalmol. 1993;111:350. doi:https://doi.org/10.1001/archopht.1993.01090030068041.
   PubMed Web of Science ®Google Scholar
• Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol. 1995;113(8):1041. doi:https://doi.org/10.1001/archopht.1995.01100080093034.
   PubMedGoogle Scholar
• Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of Infliximab in Behcet’s disease with refractory uveitis. J Rheumatol. 2004;31:1362–1368.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis of Behcet’s disease. Lancet. 2001;358:295–296. doi:https://doi.org/10.1016/S0140-6736(01)05497-6.
   PubMed Web of Science ®Google Scholar
• Morris DS, Gavin MP, Sturrock RD. The effect of anti-tumor necrosis factor alpha (Infliximab) on sight-threatening uveitis in a patient with Behcet’s disease. Adv Exp Med Biol. 2003;528:557–559. [48] Sayarlioglu M, Cinal A, Tropeu N, Demirok A. Effect of infliximab on refractory uveitis of Behcet’s disease. Ann Pharmacother 2004;38:901–2.
   PubMed Web of Science ®Google Scholar
• Giansanti F, Barbera ML, Virgili G, Pieri B, Emmi L, Menchini U. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet’s disease. Eur J Ophthalmol. 2004;14:445. doi:https://doi.org/10.1177/112067210401400515.
   PubMed Web of Science ®Google Scholar
• Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, et al. Long-term treatment of refractory posterior uveitis with anti-TNFα (infliximab). Eye. 2005;19:841–845. doi:https://doi.org/10.1038/sj.eye.6701689.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent sight-threatening ocular inflammation in adamantiades-Behc ̧et disease. Ann Intern Med. 2004;140:404–406. doi:https://doi.org/10.7326/0003-4819-140-5-200403020-00025.
   PubMed Web of Science ®Google Scholar
• Wechsler B, Sablé-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behcet’s disease. Clin Exp Rheumatol. 2004;22(Suppl. 34):S14–6.
   PubMedGoogle Scholar